Please provide your email address to receive an email when new articles are posted on . A Bay Area neurotechnology firm has announced the commercial release of a novel artificial intelligence-based ...
With the decision, ClarityPro becomes the first and only device to offer new technology add-on payment reimbursement for the diagnosis of electrographic status epilepticus. The FDA has granted 510(k) ...
The underlying cause of status epilepticus is strongly associated with the likelihood of neurologic recovery, but does not independently predict short-term mortality. 2. Nonconvulsive status ...
RADNOR, Pa.--(BUSINESS WIRE)--Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results